Summary
Introduction
Theratechnologies is a Canadian biopharmaceutical company developing therapeutic peptides for endocrine and metabolic disorders. The company has developed its product pipeline utilizing two technologies ExoPep and LAP (Long Acting Peptide).
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company's pipeline products include: TH9507 being developed for HIV-Associated Lipodystrophy (Phase III); ThGRF being developed for growth hormone deficiency (Phase I), and cystic fibrosis (Phase I); and THG213.29 being developed for renal disease (preclinical). The company recognizes revenues in the form of royalties, and interest on investments from other pharmaceutical/biotechnology companies like ALZA pursuant to its co-development agreements. The company's total revenues declined at a CAGR of 33.8% from $7.6 million to $1.5 million during the period 2002-2006. This represents an absolute decline of -$6.1 million for the period of analysis. The company derived its revenues from royalties, and interest on investments.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
